Smart Innovation
Antimicrobial resistance (AMR)
AMR develops when bacteria, fungi or viruses are exposed to antibiotics, antifungals or antivirals. As a result, the antimicrobials become ineffective and infections may persist. In addition, medical interventions including surgery, chemotherapy and stem cell therapy may become impossible.
AMR is considered the biggest global threat of Health and Food Safety.
AMR Insights
For Researchers and Entrepreneurs who wish to investigate, develop and commercialize novel vaccines, diagnostics and antimicrobials to prevent Antimicrobial resistance, AMR Insights offers selected, global information and data, specific education and extensive networking and partnering opportunities.
AMR Insights is for:
- Researchers at Universities and University Medical Centers
- Researchers at Research Institutes
- R&D professionals in Pharma, Biopharma and Diagnostics companies
- Entrepreneurs in start-up’s and spin off companies
- Innovators, Venture Capitalists.
Latest Topics
-
18 September 2025Artificial intelligence and infectious diseases: tackling antimicrobial resistance, from personalised care to antibiotic discovery
Antimicrobial resistance (AMR) poses a major threat to global health, as recognized in the recent UN General Assembly High-Level Statement on AMR. Key priorities include new antibiotics, stewardship, surveillance, and infection prevention. Artificial intelligence (AI) could accelerate progress by uncovering hidden data patterns and supporting clinical decision-making. Potential applications span drug discovery, stewardship, diagnostics, surveillance, […]
Read more... -
12 September 2025Automated phage therapy in smart hospitals: a hypothesis for an AI, metagenomics, and IoT pipeline to treat resistant infections
This hypothesis outlines a vision for an AI-driven, fully automated phage therapy pipeline in smart hospitals to address antimicrobial resistance. The system integrates physics-informed neural networks to optimise personalised dosing, AI algorithms for rapid phage selection from validated banks, IoT-enabled robotic delivery, and real-time metagenomic feedback to monitor efficacy and adapt treatment. Designed as a […]
Read more... -
10 September 2025Bridging the fair share gap for antibacterial innovation: an observational analysis of antibacterial revenues in the G7 and EU27
Antimicrobial resistance requires stronger investment in antibacterial R&D, yet G7+EU27 countries are falling short of their “fair share” contributions to pull incentives. Using GDP-based targets (US$258–562M annually) and revenue data for cefiderocol and ceftazidime-avibactam (2015–2024), the study finds that only the UK (via its subscription program) and Italy (through higher use and an “orphan” drug […]
Read more...
More news related to Smart innovation
